GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (STU:8ZD) » Definitions » EV-to-EBIT

Abbisko Cayman (STU:8ZD) EV-to-EBIT : 10.09 (As of Nov. 13, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Abbisko Cayman EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Abbisko Cayman's Enterprise Value is €82.32 Mil. Abbisko Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €8.16 Mil. Therefore, Abbisko Cayman's EV-to-EBIT for today is 10.09.

The historical rank and industry rank for Abbisko Cayman's EV-to-EBIT or its related term are showing as below:

STU:8ZD' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.27   Med: 0.98   Max: 14.05
Current: 10.66

During the past 5 years, the highest EV-to-EBIT of Abbisko Cayman was 14.05. The lowest was -2.27. And the median was 0.98.

STU:8ZD's EV-to-EBIT is ranked worse than
54.37% of 423 companies
in the Biotechnology industry
Industry Median: 10.67 vs STU:8ZD: 10.66

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Abbisko Cayman's Enterprise Value for the quarter that ended in Jun. 2024 was €-30.14 Mil. Abbisko Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €8.16 Mil. Abbisko Cayman's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -27.08%.


Abbisko Cayman EV-to-EBIT Historical Data

The historical data trend for Abbisko Cayman's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman EV-to-EBIT Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -1.20 0.90 -0.52

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only - 0.90 - -0.52 -

Competitive Comparison of Abbisko Cayman's EV-to-EBIT

For the Biotechnology subindustry, Abbisko Cayman's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbisko Cayman's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's EV-to-EBIT falls into.



Abbisko Cayman EV-to-EBIT Calculation

Abbisko Cayman's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=82.316/8.162
=10.09

Abbisko Cayman's current Enterprise Value is €82.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €8.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbisko Cayman  (STU:8ZD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Abbisko Cayman's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=8.162/-30.142514
=-27.08 %

Abbisko Cayman's Enterprise Value for the quarter that ended in Jun. 2024 was €-30.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €8.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbisko Cayman EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman Headlines

No Headlines